Emerging Psoriasis Therapies go Head-to-Head with Marketed Drugs to Win over Physicians, Patients and Payors
The market for moderate-to-severe plaque psoriasis therapeutics is becoming increasingly competitive with the imminent arrival of three promising new drug classes: interleukin-17(IL-17) inhibitors, a janus kinase (JAK) inhibitor, and a phosphodiesterase-4 (PDE-4) inhibitor, the last two being oral therapies. These drugs are welcomed additions to the toolbox of therapeutic options available to patients and physicians for an indication historically underserved by novel therapies. The increasingly competitive pipeline is also raising the bar for new entrants.
Recent analysis from Frost & Sullivan’s Product and Pipeline Analysis of the Global Psoriasis Therapeutics Market finds the development pipeline for moderate-to-severe psoriasis therapeutics has at least 37 investigational biologic and small molecule drugs in various stages of development. The particularly competitive classes include IL-17 with three candidates in the late stages development and anti-interleukin-23 (IL-23), with five candidates in various stages of development.
“The discovery of the role of tumour necrosis factor alpha (TNFα) in inflammatory diseases led to the commercial launch of several popular TNF blockers,” said a Frost & Sullivan Life Sciences analyst. “These highly effective therapies for severe cases of plaque psoriasis are being upstaged by several new drug classes with improved efficacy, safety and tolerability.”
Although next-generation biopharmaceuticals and novel oral therapies offer superior efficacy and safety, roadblocks, in the form of inadequate clinical differentiation and endorsement of pharmacoeconomic benefits, exist. Hence, pharmaceuticals are lining up numerous head-to-head trials to demonstrate the superiority of their therapies over marketed drugs.
Further, regulator and payer scrutiny of new therapies for chronic plaque psoriasis is increasing, and the bar for approval and reimbursement is significantly higher than it was a decade ago. The availability of several effective and approved TNF blockers for the treatment of the disease places additional pressure on the developers of novel therapies to demonstrate superior profiles in terms of efficacy, safety, tolerability and patient acceptance.
“If the cost and safety profiles are comparable, therapies that offer better patient convenience will be preferred to improve adherence to therapy and prevent relapse,” noted the analyst. “Advanced devices and improvements in formulations to reduce the inconvenience of frequent injections could set otherwise similar products apart in the eyes of patients.”
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance